The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
Participants must have at least three joints that are affected by arthritis.
Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
Participants must not have been diagnosed with JPsA before 5 years of age.
Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
Other protocol-defined Inclusion/Exclusion criteria apply.
Parallel
Deucravacitinib
DrugSpecified dose on specified days
Placebo
Other interventionSpecified dose on specified days
Time to first flare during the withdrawal period
Trough concentration at steady state (Cminss)
Time-averaged steady-state concentration (Cavgss)
Steady-state maximum observed concentration (Cmaxss)
Number of participants with flare during the withdrawal period
Click on the lead sponsor to view all of their trials.
